Topics

Lantheus to acquire oncology company Progenics Pharmaceuticals

03:58 EDT 3 Oct 2019 | Pharmaceutical Business Review

As per terms of the deal, Progenics shareholders will secure 0.2502 shares of Lantheus stock for each share of Progenics stock, representing around 35% aggregate ownership interest in

The post Lantheus to acquire oncology company Progenics Pharmaceuticals appeared first on Pharmaceutical Business review.

Original Article: Lantheus to acquire oncology company Progenics Pharmaceuticals

NEXT ARTICLE

More From BioPortfolio on "Lantheus to acquire oncology company Progenics Pharmaceuticals"

Quick Search